ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. sjá kafla 4. 4 og 5.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - Ónæmisbælandi lyf - simulect er ætlað til að fyrirbyggja bráðan líffæraútgáfu í nýsköpun á nýru í nýrum hjá fullorðnum og börnum (1-17 ára). Það er til þess að vera notuð samhliða með ciclosporin fyrir microemulsion - og barksteri byggir ónæmisbæling, í sjúklinga með spjaldið viðbrögð mótefni minna en 80%, eða þrefaldur viðhald ónæmisbælandi meðferð inniheldur ciclosporin fyrir microemulsion, krefur og annaðhvort azatíóprín eða mycofenolatmofetils.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - Ónæmisbælandi lyf - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 360 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg